Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shot up 6% during trading on Friday . The company traded as high as $114.79 and last traded at $113.89, 4,295,304 shares traded hands during mid-day trading. An increase of 138% from the average session volume of 1,801,632 shares. The stock had previously closed at $107.42.
Several equities research analysts recently commented on ALXN shares. Credit Suisse Group cut their price target on shares of Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. SunTrust Banks assumed coverage on shares of Alexion Pharmaceuticals in a research note on Tuesday, November 12th. They issued a “buy” rating and a $125.00 price objective for the company. TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 15th. ValuEngine upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $156.37.
The business’s 50 day simple moving average is $108.47 and its 200 day simple moving average is $112.81. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.45. The company has a market capitalization of $24.40 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 1.08 and a beta of 1.67.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, topping the consensus estimate of $2.47 by $0.32. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the prior year, the firm earned $2.02 earnings per share. The business’s quarterly revenue was up 23.0% compared to the same quarter last year. As a group, analysts expect that Alexion Pharmaceuticals, Inc. will post 9.43 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of ALXN. Nuveen Asset Management LLC lifted its position in Alexion Pharmaceuticals by 57,650.8% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock worth $476,393,000 after acquiring an additional 3,630,846 shares during the period. Redmile Group LLC purchased a new stake in shares of Alexion Pharmaceuticals during the third quarter worth approximately $113,826,000. Renaissance Technologies LLC lifted its holdings in shares of Alexion Pharmaceuticals by 104.9% during the second quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock worth $215,140,000 after purchasing an additional 840,742 shares during the period. Prudential Financial Inc. lifted its holdings in shares of Alexion Pharmaceuticals by 87.0% during the second quarter. Prudential Financial Inc. now owns 1,180,067 shares of the biopharmaceutical company’s stock worth $154,565,000 after purchasing an additional 549,063 shares during the period. Finally, Worldquant Millennium Advisors LLC grew its position in Alexion Pharmaceuticals by 429.2% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 504,514 shares of the biopharmaceutical company’s stock valued at $49,412,000 after buying an additional 409,180 shares during the last quarter. 91.60% of the stock is owned by hedge funds and other institutional investors.
Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Recommended Story: Roth IRA
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.